TEMPUS AI : PARTNERS WITH VERASTEM TO DEVELOP CDX FOR FDA-APPROVED KRAS-MUTANT RECURRENT LOW-GRADE OVARIAN CANCER COMBINATION TREATMENT

Reuters · 05/20/2025 12:34

Please log in to view news